stoxline Quote Chart Rank Option Currency Glossary
NeuroSense Therapeutics Ltd. (NRSN)
0.735  -0.061 (-7.66%)    12-08 16:00
Open: 0.7578
High: 0.78
Volume: 338,332
Pre. Close: 0.796
Low: 0.7
Market Cap: 10(M)
Technical analysis
2023-12-08 4:45:02 PM
Short term     
Mid term     
Targets 6-month :  1.27 1-year :  1.75
Resists First :  1.09 Second :  1.5
Pivot price 0.86
Supports First :  0.43 Second :  0.35
MAs MA(5) :  0.97 MA(20) :  0.77
MA(100) :  0.8 MA(250) :  1.31
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  27.3 D(3) :  43.4
RSI RSI(14): 48
52-week High :  2.91 Low :  0.4
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NRSN ] has closed above bottom band by 38.9%. Bollinger Bands are 270.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.78 - 0.78 0.78 - 0.79
Low: 0.69 - 0.69 0.69 - 0.7
Close: 0.73 - 0.73 0.73 - 0.74
Company Description

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Headline News

Wed, 06 Dec 2023
Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth? - Simply Wall St

Tue, 05 Dec 2023
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints - PR Newswire

Tue, 05 Dec 2023
Neurosense Therapeutics Ltd (NRSN) has gained 42.95% Tuesday In Premarket Trading - InvestorsObserver

Mon, 04 Dec 2023
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints ... - PR Newswire

Mon, 04 Dec 2023
Will Neurosense Therapeutics Ltd (NRSN) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Fri, 01 Dec 2023
Where Does Neurosense Therapeutics Ltd (NRSN) Stock Fall in the Biotechnology Field After It Has Gained 75.00% This Week? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 14 (M)
Shares Float 7 (M)
Held by Insiders 36.8 (%)
Held by Institutions 0.9 (%)
Shares Short 234 (K)
Shares Short P.Month 44 (K)
Stock Financials
EPS -0.94
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.02
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -114.6 %
Return on Equity (ttm) -300.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.99
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.79
PEG Ratio 0
Price to Book value -36.75
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android